PE20211397A1 - Moduladores de la expresion de apol1 - Google Patents
Moduladores de la expresion de apol1Info
- Publication number
- PE20211397A1 PE20211397A1 PE2020001880A PE2020001880A PE20211397A1 PE 20211397 A1 PE20211397 A1 PE 20211397A1 PE 2020001880 A PE2020001880 A PE 2020001880A PE 2020001880 A PE2020001880 A PE 2020001880A PE 20211397 A1 PE20211397 A1 PE 20211397A1
- Authority
- PE
- Peru
- Prior art keywords
- apol1
- modified
- modulators
- seq
- reducing
- Prior art date
Links
- 102100030762 Apolipoprotein L1 Human genes 0.000 title abstract 4
- 101100323521 Homo sapiens APOL1 gene Proteins 0.000 title abstract 4
- 108091034117 Oligonucleotide Proteins 0.000 abstract 3
- 239000002777 nucleoside Substances 0.000 abstract 2
- 102000018757 Apolipoprotein L1 Human genes 0.000 abstract 1
- 108010052469 Apolipoprotein L1 Proteins 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 208000017169 kidney disease Diseases 0.000 abstract 1
- 108020004999 messenger RNA Proteins 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 238000012986 modification Methods 0.000 abstract 1
- 230000004048 modification Effects 0.000 abstract 1
- 150000002829 nitrogen Chemical class 0.000 abstract 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 1
- 125000003835 nucleoside group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C12N2310/3341—5-Methylcytosine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
- C12N2310/3525—MOE, methoxyethoxy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/35—Special therapeutic applications based on a specific dosage / administration regimen
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862674865P | 2018-05-22 | 2018-05-22 | |
| PCT/US2019/033244 WO2019226611A1 (en) | 2018-05-22 | 2019-05-21 | Modulators of apol1 expression |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20211397A1 true PE20211397A1 (es) | 2021-07-27 |
Family
ID=68613945
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2020001880A PE20211397A1 (es) | 2018-05-22 | 2019-05-21 | Moduladores de la expresion de apol1 |
Country Status (27)
| Country | Link |
|---|---|
| US (4) | US10927377B2 (enExample) |
| EP (1) | EP3799570A4 (enExample) |
| JP (3) | JP7247227B2 (enExample) |
| KR (2) | KR20250153881A (enExample) |
| CN (3) | CN118127019A (enExample) |
| AR (1) | AR115416A1 (enExample) |
| AU (2) | AU2019274461B2 (enExample) |
| BR (1) | BR112020023436A2 (enExample) |
| CA (1) | CA3099750A1 (enExample) |
| CL (1) | CL2020003010A1 (enExample) |
| CO (1) | CO2020015377A2 (enExample) |
| CR (1) | CR20200631A (enExample) |
| EA (1) | EA202092748A1 (enExample) |
| EC (1) | ECSP20082339A (enExample) |
| IL (2) | IL316397A (enExample) |
| JO (1) | JOP20200291A1 (enExample) |
| MA (1) | MA53924A (enExample) |
| MX (2) | MX2020012497A (enExample) |
| MY (1) | MY200352A (enExample) |
| NI (1) | NI202000085A (enExample) |
| PE (1) | PE20211397A1 (enExample) |
| PH (1) | PH12020551995A1 (enExample) |
| SG (1) | SG11202011397QA (enExample) |
| TW (2) | TWI841564B (enExample) |
| UA (1) | UA128819C2 (enExample) |
| WO (1) | WO2019226611A1 (enExample) |
| ZA (1) | ZA202007537B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE49076E1 (en) | 2010-04-18 | 2022-05-17 | Beth Israel Deaconess Medical Center, Inc. | Compositions and methods for treating renal disease |
| IL316397A (en) | 2018-05-22 | 2024-12-01 | Ionis Pharmaceuticals Inc | Modulators of APOL1 expression |
| IL283592B2 (en) | 2018-12-17 | 2025-08-01 | Vertex Pharma | Inhibitors of apol1 and methods of using same |
| EP4097083A1 (en) | 2020-01-29 | 2022-12-07 | Vertex Pharmaceuticals Incorporated | Inhibitors of apol1 and methods of using same |
| CN116157393A (zh) | 2020-06-12 | 2023-05-23 | 弗特克斯药品有限公司 | Apol1的抑制剂及其用途 |
| EP4165036A1 (en) | 2020-06-12 | 2023-04-19 | Vertex Pharmaceuticals Incorporated | Solid forms of apol1 inhibitor and using the same |
| KR20240149461A (ko) | 2022-01-18 | 2024-10-14 | 메이즈 테라퓨틱스, 인코퍼레이티드 | Apol1 저해제 및 사용 방법 |
| EP4573077A1 (en) * | 2022-08-19 | 2025-06-25 | Maze Therapeutics, Inc. | Apol1 inhibitors and methods of use |
| TW202545540A (zh) | 2024-05-21 | 2025-12-01 | 瑞典商阿斯特捷利康公司 | 用於治療ａｐｏｌ１介導之腎病之方法 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020082401A1 (en) | 1994-12-15 | 2002-06-27 | Yeda Research And Development Company | Modulators of the function of FAS/APO1 receptors |
| US6833361B2 (en) * | 1998-05-26 | 2004-12-21 | Ribapharm, Inc. | Nucleosides having bicyclic sugar moiety |
| WO2002028999A2 (en) | 2000-10-03 | 2002-04-11 | Gene Logic, Inc. | Gene expression profiles in granulocytic cells |
| USH2191H1 (en) | 2000-10-24 | 2007-06-05 | Snp Consortium | Identification and mapping of single nucleotide polymorphisms in the human genome |
| US20070054278A1 (en) | 2003-11-18 | 2007-03-08 | Applera Corporation | Polymorphisms in nucleic acid molecules encoding human enzyme proteins, methods of detection and uses thereof |
| US20050171044A1 (en) | 2003-12-24 | 2005-08-04 | Stein David A. | Oligonucleotide compound and method for treating nidovirus infections |
| WO2006034348A2 (en) | 2004-09-17 | 2006-03-30 | Isis Pharmaceuticals, Inc. | Enhanced antisense oligonucleotides |
| EP1867338A1 (en) | 2006-05-30 | 2007-12-19 | Université Libre De Bruxelles | Pharmaceutical composition comprising apolipoproteins for the treatment of human diseases |
| JP2010507387A (ja) | 2006-10-25 | 2010-03-11 | クアーク・ファーマスーティカルス、インコーポレイテッド | 新規のｓｉＲＮＡおよびその使用方法 |
| CA2739464C (en) | 2008-10-03 | 2020-03-31 | Curna, Inc. | Treatment of apolipoprotein-a1 related diseases by inhibition of natural antisense transcript to apolipoprotein-a1 |
| CN102307997B (zh) | 2008-12-04 | 2018-03-30 | 库尔纳公司 | 通过抑制针对沉默调节蛋白1的天然反义转录物来治疗沉默调节蛋白1(sirt1)相关的疾病 |
| WO2011020865A1 (en) | 2009-08-18 | 2011-02-24 | Universite Libre De Bruxelles | Apolipoprotein l- i variants and their use |
| JP5991922B2 (ja) | 2009-11-13 | 2016-09-14 | サレプタ セラピューティクス， インコーポレイテッド | アンチセンス抗ウイルス性化合物およびインフルエンザウイルス感染を処置するための方法 |
| JP6031356B2 (ja) | 2009-12-23 | 2016-11-24 | カッパーアールエヌエー，インコーポレイテッド | Ｕｃｐ２に対する天然アンチセンス転写産物の阻害による脱共役タンパク質２（ｕｃｐ２）関連疾患の治療 |
| US9023355B2 (en) * | 2010-04-13 | 2015-05-05 | Beth Israel Deaconess Medical Center, Inc. | Compositions and methods for treating renal disease |
| US20120003644A1 (en) | 2010-06-07 | 2012-01-05 | Rappaport Family Institute For Research In The Medical Sciences | Methods and kits for determining predisposition to develop kidney diseases |
| CA2863958A1 (en) * | 2012-02-08 | 2013-08-15 | Isis Pharmaceuticals, Inc. | Methods and compositions for modulating factor vii expression |
| HUE051680T2 (hu) | 2012-05-24 | 2021-03-29 | Ionis Pharmaceuticals Inc | Apolipoprotein(a) expressziójának módosítására szolgáló eljárások és készítmények |
| WO2014078213A2 (en) | 2012-11-16 | 2014-05-22 | Merck Sharp & Dohme Corp. | Modified apol1 polypeptides |
| WO2014085154A1 (en) | 2012-11-27 | 2014-06-05 | Beth Israel Deaconess Medical Center, Inc. | Methods for treating renal disease |
| US20160003808A1 (en) | 2013-03-14 | 2016-01-07 | Galapagos Nv | Molecular targets and compounds, and methods to identify the same, useful in the treatment of diseases associated with epithelial mesenchymal transition |
| GB201311057D0 (en) | 2013-06-21 | 2013-08-07 | Univ Greenwich | Antisense oligonucleotide compositions |
| TWI657819B (zh) * | 2013-07-19 | 2019-05-01 | 美商Ionis製藥公司 | 用於調節τ蛋白表現之組合物 |
| WO2015136509A2 (en) | 2014-03-14 | 2015-09-17 | Genesis Theranostix Korlatolt Felelossegu Tarsasag | Diagnostic and therapeutic targets for preeclampsia and closely related complications of pregnancy |
| CN116970607A (zh) | 2014-03-19 | 2023-10-31 | Ionis制药公司 | 用于调节共济失调蛋白2表达的组合物 |
| EP3020813A1 (en) | 2014-11-16 | 2016-05-18 | Neurovision Pharma GmbH | Antisense-oligonucleotides as inhibitors of TGF-R signaling |
| TW201718010A (zh) * | 2015-06-19 | 2017-06-01 | 健臻公司 | 治療原發性局部節段性腎小球硬化症之方法 |
| IL318703A (en) | 2015-06-29 | 2025-03-01 | Caris Science Inc | Therapeutic oligonucleotides |
| HK1255699A1 (zh) * | 2015-09-24 | 2019-08-23 | Ionis Pharmaceuticals, Inc. | Kras表达的调节剂 |
| IL316397A (en) | 2018-05-22 | 2024-12-01 | Ionis Pharmaceuticals Inc | Modulators of APOL1 expression |
-
2019
- 2019-05-21 IL IL316397A patent/IL316397A/en unknown
- 2019-05-21 CN CN202410386618.XA patent/CN118127019A/zh active Pending
- 2019-05-21 TW TW108117504A patent/TWI841564B/zh active
- 2019-05-21 EA EA202092748A patent/EA202092748A1/ru unknown
- 2019-05-21 CN CN202410386621.1A patent/CN118127020A/zh active Pending
- 2019-05-21 US US16/418,060 patent/US10927377B2/en active Active
- 2019-05-21 AU AU2019274461A patent/AU2019274461B2/en active Active
- 2019-05-21 WO PCT/US2019/033244 patent/WO2019226611A1/en not_active Ceased
- 2019-05-21 PE PE2020001880A patent/PE20211397A1/es unknown
- 2019-05-21 KR KR1020257034730A patent/KR20250153881A/ko active Pending
- 2019-05-21 EP EP19807789.3A patent/EP3799570A4/en active Pending
- 2019-05-21 SG SG11202011397QA patent/SG11202011397QA/en unknown
- 2019-05-21 CN CN201980033544.9A patent/CN112423792B/zh active Active
- 2019-05-21 MY MYPI2020006084A patent/MY200352A/en unknown
- 2019-05-21 JO JOP/2020/0291A patent/JOP20200291A1/ar unknown
- 2019-05-21 CR CR20200631A patent/CR20200631A/es unknown
- 2019-05-21 KR KR1020207036583A patent/KR102874776B1/ko active Active
- 2019-05-21 IL IL278785A patent/IL278785B2/en unknown
- 2019-05-21 CA CA3099750A patent/CA3099750A1/en active Pending
- 2019-05-21 UA UAA202007818A patent/UA128819C2/uk unknown
- 2019-05-21 MX MX2020012497A patent/MX2020012497A/es unknown
- 2019-05-21 BR BR112020023436-2A patent/BR112020023436A2/pt unknown
- 2019-05-21 JP JP2020565431A patent/JP7247227B2/ja active Active
- 2019-05-21 TW TW113114934A patent/TW202430638A/zh unknown
- 2019-05-21 MA MA053924A patent/MA53924A/fr unknown
- 2019-05-22 AR ARP190101365A patent/AR115416A1/es unknown
-
2020
- 2020-09-18 US US17/025,239 patent/US11525136B2/en active Active
- 2020-11-18 PH PH12020551995A patent/PH12020551995A1/en unknown
- 2020-11-19 CL CL2020003010A patent/CL2020003010A1/es unknown
- 2020-11-20 NI NI202000085A patent/NI202000085A/es unknown
- 2020-11-20 MX MX2025003294A patent/MX2025003294A/es unknown
- 2020-12-03 ZA ZA2020/07537A patent/ZA202007537B/en unknown
- 2020-12-09 CO CONC2020/0015377A patent/CO2020015377A2/es unknown
- 2020-12-18 EC ECSENADI202082339A patent/ECSP20082339A/es unknown
-
2022
- 2022-11-08 US US18/053,447 patent/US12168766B2/en active Active
-
2023
- 2023-03-15 JP JP2023040313A patent/JP7645301B2/ja active Active
-
2024
- 2024-11-06 JP JP2024194079A patent/JP2025013513A/ja active Pending
- 2024-11-07 US US18/939,901 patent/US20250066785A1/en active Pending
-
2025
- 2025-10-31 AU AU2025259982A patent/AU2025259982A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2022002622A2 (es) | Anticuerpos anti-cd73 y composiciones | |
| MX2022004101A (es) | Composiciones de oligonucleotidos y metodos de uso de las mismas. | |
| MA52742B1 (fr) | Anticorps bispécifiques dll3-cd3 | |
| MX2023001538A (es) | Composiciones y metodos para inhibir la expresion de lpa. | |
| CL2020000498A1 (es) | Composiciones farmacéuticas que contienen anticuerpos contra la glicoproteína del virus ébola. (divisional solicitud 201701920) | |
| AR124358A1 (es) | Formulación | |
| MX2020002710A (es) | Molecula de union al antigeno multiespecifica que tiene actividad de sustitucion de la funcion de cofactor del factor viii de coagulacion de sangre (fviii) y formulacion farmaceutica que contiene tal molecula como ingrediente activo. | |
| MD4685B1 (ro) | Metodă de tratament al stărilor asociate cu activarea complementului dependentă de MASP-2 | |
| WO2018069500A3 (en) | Anti-lag-3 antibodies and compositions | |
| PE20141019A1 (es) | Nuevos inmunoconjugados | |
| MX2020003472A (es) | Variante e isoforma de anticuerpos con actividad biologica reducida. | |
| PE20191347A1 (es) | Anticuerpos procoagulantes | |
| CL2019001049A1 (es) | Vacuna contra parvovirus porcino. | |
| CR9428A (es) | Metodos para el tratamiento y la prevencion de fibrosis | |
| JOP20200021A1 (ar) | طرق للعلاج و/أو الوقاية من داء الطعم حيال الثوي و/أو نزف سنخي منتشر و/أو داء الانسداد الوريدي المرتبط بطعم خلية جذعية مكونة للدم | |
| CU23856A3 (es) | Composiciones que comprenden anticuerpo monoclonal chir-12.12 | |
| MX2018004307A (es) | Composiciones y metodos para modular la expresion de angiotensinogeno. | |
| MX2019010318A (es) | Composiciones limpiadoras cosmeticas. | |
| PE20190626A1 (es) | Composiciones y metodos para modular la expresion del factor b del complemento | |
| MX2018007726A (es) | Composiciones y metodos para disminuir la expresion de tau. | |
| PE20191484A1 (es) | Moduladores de la expresion de pcsk9 | |
| MX2022001719A (es) | Formulaciones de conjugados de benzazepina y usos de las mismas. | |
| PE20131065A1 (es) | Composiciones farmaceuticas combinadas y metodo de tratamiento del vertigo, la cinetosis y la distonia vegetativa-vascular | |
| AR105350A1 (es) | Composición de limpieza con propelente | |
| CO2020013690A2 (es) | Composiciones y métodos para el tratamiento de la distrofia macular |